Van Poppel H, Nilsson S, Algaba F, Bergerheim U, Dal Cin P, Fleming S, Hellsten S, Kirkali Z, Klotz L, Lindblad P, Ljungberg B, Mulders P, Roskams T, Ross R K, Walker C, Wersäll P
Department of Urology, University Hospital K.U. Leuven, Belgium.
Scand J Urol Nephrol Suppl. 2000(205):136-65.
Renal cell carcinoma (RCC), although occurring less frequently than prostate and bladder cancer, is actually the most malignant urologic disease, killing >35% of affected patients. Therefore, investigation of the nature of premalignant lesions of the kidney is a relevant issue. Following the most recent histological classification RCC can be subdivided into four categories: conventional RCC; papillary RCC; chromophobe RCC; and collecting duct carcinoma. In contrast to many genitourinary malignancies, premalignant alterations in the kidney are scarcely described. Intratubular epithelial dysplasia has been recognized as the most common precursor of RCC. In analogy to prostatic intraepithelial neoplasia (PIN), the premalignant lesions of the kidney are described as high or low-grade renal intratubular neoplasia. In contrast, precancerous lesions have been described as part of the von Hippel-Lindau syndrome (VHL) where the evolution from a simple cyst to an atypical cyst with epithelial hyperplasia to cystic or solid conventional-type RCC is well documented. Finally, in the genesis of papillary RCC an adenoma-carcinoma sequence has been recognized with specific genetic changes. There are no data on the epidemiology of premalignant lesions of the kidney, but research into the etiology of RCC has been extended substantially. Familial and genetic factors are well documented in VHL disease, in hereditary papillary RCC, in the tuberous sclerosis complex and in familial RCC. Cigarette smoking and obesity are established risk factors for RCC. Hypertension or its medication has also been associated with an increased risk. Among dietary factors an inverse relation between risk and consumption of vegetables and fruit has been found. Occupational exposure to substances such as asbestos and solvents has been linked to an increased risk of RCC. Specific RCC variants have distinctive chromosome alterations and several genes have been implicated in the development of RCC. Loss of material from the 3p chromosome characterizes conventional RCC and the deletion of the VHL suppressor gene plays an important role in the genesis of this RCC variant. In contrast, numerical changes with trisomy of chromosomes 7 and 17 and loss of the sex chromosome are typical changes in papillary tumors, whereas papillary RCC have additional trisomies. Chromophobe RCC is characterized by loss of chromosomes with a combination of monosomies. Less consistent genetic alterations are associated with collecting duct carcinoma. The traditional treatment of RCC is surgery by radical or partial nephrectomy. The latter approach carries a risk of tumor recurrence as a result of unrecognized satellite lesions or premalignant lesions that might have been present at the time of surgery. However, the reported recurrence rates after partial nephrectomy are <1% and therefore the possible presence of premalignant disease does not alter the actual treatment strategy advocated. Although multifocality and bilateral occurrence of RCC are much more likely in cases of papillary RCC, biopsy of the renal remnant or contralateral kidney is not justified even in patients with this tumor type. Conversely, patients with RIN in a partial or radical nephrectomy specimen or in a renal biopsy taken for whatever reason should be subjected to closer follow-up with regularly repeated ultrasound. When an effective chemopreventive regimen becomes available it might be useful for patients with an inherited risk of RCC as well as in those who are at risk of tumor recurrence after intervention. Mass screening with the purpose of detecting RCC at its earliest stage is not recommended at the present time, but screening focused on certain risk groups can be advocated. Further research is needed to identify avoidable risks, develop effective chemoprevention and recognize patients at risk.
肾细胞癌(RCC)虽然比前列腺癌和膀胱癌发病率低,但实际上是最恶性的泌尿系统疾病,超过35%的患者会因此死亡。因此,研究肾的癌前病变性质是一个相关问题。根据最新的组织学分类,RCC可分为四类:传统型RCC;乳头状RCC;嫌色细胞性RCC;以及集合管癌。与许多泌尿生殖系统恶性肿瘤不同,肾的癌前改变鲜有描述。肾小管上皮发育异常已被认为是RCC最常见的前驱病变。类似于前列腺上皮内瘤变(PIN),肾的癌前病变被描述为高级别或低级别肾内肿瘤。相比之下,癌前病变被描述为冯·希佩尔-林道综合征(VHL)的一部分,从单纯囊肿演变为具有上皮增生的非典型囊肿,再到囊性或实性传统型RCC,这一演变过程已有充分记录。最后,在乳头状RCC的发生过程中,已认识到存在具有特定基因变化的腺瘤-癌序列。目前尚无关于肾癌前病变流行病学的数据,但对RCC病因的研究已大幅扩展。家族和遗传因素在VHL病、遗传性乳头状RCC、结节性硬化症复合体和家族性RCC中已有充分记录。吸烟和肥胖是已确定的RCC危险因素。高血压或其治疗药物也与风险增加有关。在饮食因素方面,已发现风险与蔬菜和水果的摄入量呈负相关。职业接触石棉和溶剂等物质与RCC风险增加有关。特定的RCC变体具有独特的染色体改变,并且有几个基因与RCC的发生有关。3号染色体物质缺失是传统型RCC的特征,VHL抑癌基因的缺失在这种RCC变体的发生中起重要作用。相比之下,7号和17号染色体三体以及性染色体丢失的数目改变是乳头状肿瘤的典型变化,而乳头状RCC还有其他三体。嫌色细胞性RCC的特征是染色体丢失并伴有单体组合。与集合管癌相关的基因改变不太一致。RCC的传统治疗方法是通过根治性或部分肾切除术进行手术。后一种方法存在肿瘤复发风险,原因是手术时可能存在未被识别的卫星病灶或癌前病变。然而,据报道部分肾切除术后的复发率<1%,因此癌前疾病的可能存在并未改变实际提倡的治疗策略。尽管乳头状RCC病例中RCC的多灶性和双侧发生更为常见,但即使是这种肿瘤类型的患者,对肾残余或对侧肾进行活检也不合理。相反,在部分或根治性肾切除标本或因任何原因进行的肾活检中发现有RIN的患者,应通过定期重复超声进行更密切的随访。当有效的化学预防方案可用时,它可能对有RCC遗传风险的患者以及干预后有肿瘤复发风险的患者有用。目前不建议进行旨在尽早发现RCC的大规模筛查,但可以提倡针对某些风险群体进行筛查。需要进一步研究以识别可避免的风险、开发有效的化学预防方法并识别有风险的患者。